UNAIDS News - March 22, 2001
A meeting took place today at WHO between staff from Cipla, WHO, UNAIDS, the European Commission and MSF, in order for the UN organizations to get clarification on a range of issues relating to Cipla's recent offer to make reduced price triple combination therapy available in developing countries. Issues raised included pre-qualification, registration requirements, supply logistics, technology transfer and validity of patents.
WHO and UNAIDS noted that an overall framework to combating the HIV/AIDS epidemic and other serious infectious diseases in poor countries is a priority. This framework must encompass prevention, care, treatment and healthcare systems development. Moreover, ensuring that antiretroviral and other AIDS drugs reach those who need them and are used effectively means that questions of financing and clinical feasibility will also have to be addressed.
The information supplied by Cipla today will be evaluated to see how Cipla's offer can be included in the information that the UN makes available to interested governments and nongovernmental organizations through its Accelerating Access Initiative.
The approach of the UNAIDS Cosponsors and the Secretariat is to help countries identify all legitimate suppliers of affordable medicines of assured quality, including those in both the generics industry and the research and development-based industry.
The UN has identified, through a public call for Expressions of Interest to manufacturers of HIV-related pharmaceuticals and diagnostic equipment, 34 suppliers of HIV-related medicines and diagnostics, 29 of which are from the generics industry. An analysis of these offers will be made publicly available in mid-2001. Cipla's offer will be included in this analysis.
010322
UN010301
Copyright © 2001 - Joint United Nations Programme on HIV/AIDS (UNAIDS). All rights reserved. UNAIDS articles, which are not formal publications of UNAIDS, may be freely reviewed, quoted, reproduced or translated, in part or in full, provided the source is acknowledged. The documents may not be sold or used in conjunction with commercial purposes without prior written approval from UNAIDS (contact: UNAIDS Information Centre).
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. AEGiS & the Sisters of Saint Elizabeth of Hungary. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS and the Sisters of Saint. Elizabeth of Hungary, or the party credited as the provider of the content.